Zhitong Finance App News, Hainan Haiyao (000566.SZ) issued an announcement. Recently, Haikou Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, obtained the “Drug Registration Certificate” for the chemical “injectable isaconazole sulfate” approved and issued by the State Drug Administration.

Isaconazole is a new generation of broad-spectrum triazole antifungal drugs used to treat aggressive aspergillus infections and invasive pilomycosis infections. It has good water solubility, high bioavailability, and predictable linear pharmacokinetic properties. There are no nephrotoxic risk excipients such as cyclodextrin used by other antifungal agents in the injection form, which are rapidly converted into active metabolites by plasma esterase after entering the body. The side chain in its structural molecule has a high affinity with the fungal CYP51 protein, which promotes it to have a broad antimycotic spectrum, including fungi that are resistant to other azole antimycotics.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.